Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 16